Credit Suisse’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $25M | Sell |
286,650
-25,343
| -8% | -$2.27M | 0.02% | 571 |
|
|
2023
Q4 | $30.1M | Sell |
311,993
-25,672
| -8% | -$2.27M | 0.03% | 540 |
|
|
2023
Q3 | $29.9M | Sell |
337,665
-6,009
| -2% | -$535K | 0.03% | 528 |
|
|
2023
Q2 | $29.8M | Sell |
343,674
-155,123
| -31% | -$14.6M | 0.03% | 551 |
|
|
2023
Q1 | $48.5M | Sell |
498,797
-8,355
| -2% | -$866K | 0.05% | 412 |
|
|
2022
Q4 | $52.5M | Buy |
507,152
+24,331
| +5% | +$2.28M | 0.06% | 377 |
|
|
2022
Q3 | $40.9M | Buy |
482,821
+47,534
| +11% | +$4.23M | 0.05% | 436 |
|
|
2022
Q2 | $36.1M | Sell |
435,287
-82,125
| -16% | -$6.54M | 0.04% | 498 |
|
|
2022
Q1 | $39.9M | Buy |
517,412
+10,418
| +2% | +$872K | 0.03% | 532 |
|
|
2021
Q4 | $44.8M | Sell |
506,994
-40,528
| -7% | -$3.34M | 0.02% | 697 |
|
|
2021
Q3 | $42.3M | Sell |
547,522
-39,839
| -7% | -$3.14M | 0.02% | 704 |
|
|
2021
Q2 | $49M | Buy |
587,361
+6,627
| +1% | +$525K | 0.03% | 700 |
|
|
2021
Q1 | $43.9M | Buy |
580,734
+9,679
| +2% | +$791K | 0.02% | 764 |
|
|
2020
Q4 | $50.1M | Buy |
571,055
+118,701
| +26% | +$9.41M | 0.02% | 718 |
|
|
2020
Q3 | $34.4M | Buy |
452,354
+17,642
| +4% | +$1.78M | 0.02% | 768 |
|
|
2020
Q2 | $53.6M | Buy |
434,712
+169,051
| +64% | +$16.8M | 0.04% | 510 |
|
|
2020
Q1 | $22.4M | Sell |
265,661
-52,195
| -16% | -$4.5M | 0.02% | 782 |
|
|
2019
Q4 | $26.9M | Buy |
317,856
+13,837
| +5% | +$1.05M | 0.02% | 862 |
|
|
2019
Q3 | $20.5M | Buy |
304,019
+11,258
| +4% | +$867K | 0.02% | 896 |
|
|
2019
Q2 | $25.1M | Buy |
292,761
+24,679
| +9% | +$2.11M | 0.02% | 798 |
|
|
2019
Q1 | $23.8M | Sell |
268,082
-42,816
| -14% | -$3.97M | 0.02% | 772 |
|
|
2018
Q4 | $26.5M | Sell |
310,898
-98,823
| -24% | -$9.4M | 0.03% | 639 |
|
|
2018
Q3 | $39.7M | Buy |
409,721
+153,851
| +60% | +$15.4M | 0.04% | 520 |
|
|
2018
Q2 | $24.1M | Sell |
255,870
-49,705
| -16% | -$4.35M | 0.02% | 738 |
|
|
2018
Q1 | $24.8M | Buy |
305,575
+48,485
| +19% | +$4.16M | 0.02% | 745 |
|
|
2017
Q4 | $22.9M | Sell |
257,090
-127,328
| -33% | -$11.1M | 0.02% | 810 |
|
|
2017
Q3 | $35.8M | Sell |
384,418
-49,788
| -11% | -$4.4M | 0.03% | 548 |
|
|
2017
Q2 | $39.4M | Sell |
434,206
-71,682
| -14% | -$6.52M | 0.04% | 499 |
|
|
2017
Q1 | $44.4M | Buy |
505,888
+76,519
| +18% | +$6.81M | 0.04% | 468 |
|
|
2016
Q4 | $35.6M | Sell |
429,369
-111,956
| -21% | -$9.63M | 0.04% | 549 |
|
|
2016
Q3 | $50.1M | Sell |
541,325
-9,308
| -2% | -$876K | 0.05% | 423 |
|
|
2016
Q2 | $42.8M | Sell |
550,633
-9,568
| -2% | -$813K | 0.05% | 437 |
|
|
2016
Q1 | $46.2M | Buy |
560,201
+73,627
| +15% | +$5.99M | 0.06% | 372 |
|
|
2015
Q4 | $51M | Buy |
486,574
+19,959
| +4% | +$2.08M | 0.06% | 370 |
|
|
2015
Q3 | $49.1M | Sell |
466,615
-119,286
| -20% | -$15.9M | 0.06% | 362 |
|
|
2015
Q2 | $80.1M | Sell |
585,901
-31,791
| -5% | -$3.94M | 0.08% | 261 |
|
|
2015
Q1 | $77M | Buy |
617,692
+32,750
| +6% | +$3.47M | 0.08% | 272 |
|
|
2014
Q4 | $52.9M | Sell |
584,942
-563,800
| -49% | -$46.9M | 0.05% | 443 |
|
|
2014
Q3 | $82.9M | Buy |
1,148,742
+52,256
| +5% | +$3.43M | 0.07% | 297 |
|
|
2014
Q2 | $68.2M | Buy |
1,096,486
+533,722
| +95% | +$32.2M | 0.06% | 355 |
|
|
2014
Q1 | $38.4M | Buy |
562,764
+135,729
| +32% | +$10M | 0.04% | 527 |
|
|
2013
Q4 | $30M | Sell |
427,035
-17,216
| -4% | -$1.17M | 0.03% | 626 |
|
|
2013
Q3 | $32.1M | Sell |
444,251
-86,414
| -16% | -$5.74M | 0.03% | 509 |
|
|
2013
Q2 | $29.6M | Buy |
+530,665
| New | +$33.1M | 0.03% | 572 |
|
Other funds holding BMRN
Credit Suisse's BMRN Position: Q1 2024 in Review
Credit Suisse reduced its BioMarin Pharmaceuticals (BMRN) stake by 8.1% in Q1 2024, selling an estimated $2.27M and leaving 286,650 shares worth $25M. The position accounts for 0.02% of the portfolio, ranked #571.
Credit Suisse first reported a position in BMRN in Q2 2013 and has held it in 44 quarters since. The position peaked at $82.9M in Q3 2014. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.
- Credit Suisse held 286,650 shares of BioMarin Pharmaceuticals worth $25M as of Q1 2024.
- Credit Suisse sold 25,343 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $2.27M.
- BioMarin Pharmaceuticals made up 0.02% of Credit Suisse's portfolio in Q1 2024, its #571 holding.
- Credit Suisse first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's BioMarin Pharmaceuticals position peaked at $82.9M in Q3 2014.
- 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.